GeneDx Holdings Corp (OQ:WGS)

Business Focus: Medical & Diagnostic Laboratories

Jan 17, 2025 04:30 pm ET
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of January 14, 2025, the compensation committee of GeneDx’s board of directors granted a total of 69,089 restricted stock units (“RSUs”) to three newly-hired employees as inducements material to each employee entering into employment with GeneDx. The foregoing includes 37,497 RSUs granted to Bryan Dechairo, as an inducement material to the employment of Mr. Dechairo as Chief Operating Officer. The RSUs were granted under GeneDx’s 2023 Equity Induceme
Jan 13, 2025 08:30 am ET
GeneDx Announces Preliminary 2024 Financial Results
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the fourth quarter and full year of 2024.
Jan 09, 2025 08:30 am ET
GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a new way to provide genetic counseling and test-ordering services for patients and families seeking access to genetic testing. The new telehealth testing pathway aims to shorten the diagnostic odyssey by connecting parents directly with
Jan 08, 2025 08:30 am ET
GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, continues its investment in advancing scientific discovery through understanding gene-disease relationships, contributing to more than 85 peer-reviewed publications in 2024. These contributions, added to GeneDx’s years of dedicated research efforts, influenced the broadening of phenotypes, the discovery of new disease mechanisms and new modes of inheritance, and ultimately impacted results of 12% of all patients who have received exome or genome sequencing from GeneDx.
Jan 02, 2025 04:01 pm ET
GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company’s executive leadership team.
Dec 16, 2024 04:05 pm ET
GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 12-16 in San Francisco, CA. Management will participate in a presentation on Wednesday, January 15, 2025, at 4:30 p.m. PT.
Dec 05, 2024 08:30 am ET
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines (Nasdaq: PRAX) and Stoke Therapeutics (Nasdaq: STOK) as the founding partners to its Patient Access Program for pediatric epilepsy, which provides access to whole exome sequencing.
Nov 22, 2024 04:05 pm ET
GeneDx to Participate in Upcoming Investor Conference
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference from December 3-5 in New York City, NY. Management will participate in a fireside chat on Tuesday, December 3, 2024, at 1:00 p.m. ET.
Nov 19, 2024 08:30 am ET
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GeneDx Discover, a first-of-its-kind data visualization tool, which provides biopharmaceutical companies access to deidentified and aggregated genetic data - powered by GeneDx’s robust database - to improve all stages of drug development. The new offering is part of GeneDx’s ongoing investment to deliver personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery.
Nov 18, 2024 08:30 am ET
GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team.
Nov 07, 2024 04:35 pm ET
New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the results of an extensive study shedding light on the critical issue of racial disparities in access to an accurate genetic diagnosis. The study, a collaboration among GeneDx, The University of Washington, Brotman Baty Institute for Precision Medicine, Geisinger and Seattle Children’s Hospital, was conducted on nearly 187,000 samples performed and across approximately 73,000 patients who received exome testing with GeneDx.
Nov 04, 2024 04:35 pm ET
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American Society of Human Genetics (ASHG) annual meeting. GeneDx data will be presented across six platform presentations and five posters and will unveil findings from key research initiatives constructed on the backbones of its industry leading diverse dataset of more than 700,000 clinical exome and genomes.
Oct 29, 2024 08:00 am ET
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third quarter of 2024.
Oct 24, 2024 11:10 am ET
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that
Oct 08, 2024 08:30 am ET
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it has provided genomic newborn screenings (gNBS) for more than 14,000 infants through its participation in groundbreaking research studies which aim to explore the clinical utility and implementation of utilizing genome sequencing to expand standard newborn screening (NBS). Through these studies, GeneDx has conducted more gNBS than any other lab and gained experience understanding diverse multi-site implementation strategies, positioning GeneDx as a laboratory leader set to revoluti
Oct 03, 2024 04:05 pm ET
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the third quarter of 2024 before the market opens on Tuesday, October 29, 2024. Management will host a conference call that day to discuss third quarter 2024 financial and operating results at 8:30 a.m. Eastern Time.
Sep 27, 2024 04:05 pm ET
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of September 23, 2024, the compensation committee of GeneDx’s board of directors granted a total of 7,700 restricted stock units (“RSUs”) to two newly hired employees as inducements material to each employee entering into employment with GeneDx. The RSUs were granted under GeneDx’s 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
Aug 12, 2024 04:05 pm ET
GeneDx to Participate in Fall Investor Conferences
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences this fall:
Aug 09, 2024 04:05 pm ET
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of June 26, 2024, the compensation committee of GeneDx’s board of directors granted seven newly hired employees 75,100 restricted stock units (“RSUs”) as inducements material to each employee entering into employment with GeneDx. The RSUs were granted under GeneDx’s 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
Jul 11, 2024 04:05 pm ET
GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024 
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2024 after the market closes on Tuesday, July 30, 2024. Management will host...
Jun 05, 2024 07:00 am ET
GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access program, developed in partnership with leading biopharma companies, which aims to increase access...
May 22, 2024 04:05 pm ET
GeneDx to Participate in Upcoming Investor Conferences
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in two upcoming investor conferences in June: Jefferies Healthcare Conference - New York City,...
Apr 29, 2024 04:05 pm ET
GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2024. “Our strong first quarter results reflect our continued dedication...
Apr 23, 2024 08:30 am ET
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry. The new partnership...
Apr 04, 2024 04:05 pm ET
GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2024 after the market closes on Monday, April 29, 2024. Management will host...
Mar 14, 2024 08:30 am ET
GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting....
Feb 26, 2024 04:05 pm ET
GeneDx to Participate in 44th Annual Cowen Health Care Conference
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Cowen Healthcare Conference from March 4-6 in Boston, MA. Management will...
Feb 20, 2024 04:26 pm ET
GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the fourth quarter and full year of 2023. “Our strong fourth quarter results were...
Feb 01, 2024 04:30 pm ET
GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024 
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter of 2023 after the market closes on Tuesday, February 20, 2024....
Jan 24, 2024 04:30 pm ET
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of January 23, 2024, the compensation committee of GeneDx’s board of directors granted newly hired employees 106,030...
Jan 08, 2024 08:55 am ET
GeneDx Announces Preliminary 2023 Financial Results
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported preliminary financial results for the fourth quarter and full year of 2023. "We had an incredibly strong...
Dec 01, 2023 08:30 am ET
GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced new data to be presented at the American Epilepsy Society (AES) annual meeting in Orlando, Florida, December 1-5, 2023,...
Nov 28, 2023 04:05 pm ET
GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Evercore ISI HealthCONx Conference this week in Miami, FL. Katherine...
Nov 27, 2023 08:31 am ET
Thinking about buying stock in Turnstone Biologics, Iterum Therapeutics, New Gold, GeneDx Holdings, or Tempest Therapeutics?
NEW YORK, Nov. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSBX, ITRM, NGD, WGS, and TPST.
Nov 20, 2023 04:05 pm ET
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of November 17, 2023, the compensation committee of GeneDx’s board of directors granted newly hired employees 10,000...
Oct 30, 2023 04:05 pm ET
GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the third quarter of 2023. "We have focused our entire company’s efforts on...
Oct 09, 2023 04:05 pm ET
GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the third quarter of 2023 after the market closes on Monday, October 30, 2023. On the...
Sep 22, 2023 04:05 pm ET
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of October 1, the compensation committee of GeneDx’s board of directors granted newly-hired employees 133,998...
Sep 11, 2023 08:00 am ET
GeneDx Announces Evolution of Executive Leadership Team
GeneDx (Nasdaq: WGS) a leader in delivering improved health outcomes through genomic and clinical insights, today announced the expansion and evolution of its executive leadership team with the appointment of Melanie Duquette as Chief Growth...
Sep 06, 2023 08:00 am ET
GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced
GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced a monumental accomplishment in its ongoing commitment to deliver personalized and actionable health insights to inform diagnosis, direct...
Aug 21, 2023 07:00 am ET
GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine
GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG) has published a...
Aug 08, 2023 08:05 pm ET
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of August 8, 2023, the compensation committee of GeneDx’s board of directors granted newly-hired employees 23,769...
Aug 08, 2023 04:05 pm ET
GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the second quarter of 2023. “Our goal at GeneDx is to end the diagnostic odyssey...
Aug 07, 2023 08:00 am ET
PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care
PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions and GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced a research...
Jul 19, 2023 07:05 am ET
GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options
GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, and Prognos Health, the largest real-world integrated data marketplace, today announced a strategic partnership to shorten the treatment odyssey for rare...
Jul 18, 2023 04:05 pm ET
GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the second quarter of 2023 after the market closes on Tuesday, August 8, 2023. On the...
Jun 28, 2023 07:00 am ET
GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will present new data on urine mitochondrial DNA testing at the 2023 United Mitochondrial Disease Foundation’s (UMDF)...
Jun 26, 2023 04:01 pm ET
GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today published a paper in Nature Methods, titled “Multiscale analysis of pangenomes enables improved representation of genomic diversity...
Jun 20, 2023 07:00 am ET
GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, applauds the decisions by the states of Florida and Arizona to provide rWGS for children in the neonatal and pediatric intensive care units...
May 24, 2023 04:05 pm ET
GeneDx to Participate in Upcoming Investor Conferences in June
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that management will participate at the following investor conferences in June: Jefferies Healthcare...
May 23, 2023 07:00 am ET
GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it will participate in multiple presentations at the World Orphan Drug Congress in Washington, D.C., May 23-25, 2023....
May 22, 2023 04:05 pm ET
GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it had received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company’s Class A...
May 09, 2023 04:05 pm ET
GeneDx Reports First Quarter 2023 Financial Results and Business Highlights
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the first quarter of 2023. “Our distinct strength in delivering genomic...
May 04, 2023 07:00 am ET
GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced the availability of its GenomeXpress® and GenomeSeqDx® whole genome sequencing tests with buccal swabs as an alternative...
May 03, 2023 01:06 pm ET
GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced a clarification regarding the CUSIP number for the Company’s public warrants. As previously disclosed on April 28, 2023,...
Apr 28, 2023 08:10 am ET
GeneDx Announces Reverse Stock Split
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that its board of directors has approved a 1-for-33 reverse stock split of the Company’s Class A common stock. The Class A...
Apr 18, 2023 04:05 pm ET
GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023. On the...
Apr 03, 2023 08:30 am ET
GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Devin K. Schaffer has been appointed General Counsel, effective April 24, 2023. As a member of the executive...
Mar 20, 2023 08:45 am ET
GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
GeneDx Holdings Corp (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it is continuing to support whole genome sequencing (WGS) and interpretation services for the...
Mar 16, 2023 08:45 am ET
GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray
GeneDx Holdings Corp. (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, announced new research today at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical...
Mar 14, 2023 04:16 pm ET
GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
GeneDx Holdings Corp. (Nasdaq: WGS) (“GeneDx” or the “Company”), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the fourth quarter and full year ended December 31,...
Mar 01, 2023 07:30 am ET
GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate at the Cowen 43rd Annual Healthcare Conference in Boston, MA. Katherine Stueland,...
Feb 28, 2023 08:30 am ET
GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced its contributions to eight posters, one platform presentation and one symposium session to be released at the upcoming 2023...
Feb 21, 2023 04:30 pm ET
GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter and full year of 2022 after the market closes on Tuesday, March...
Feb 16, 2023 08:30 am ET
GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases
GeneDx Holdings Corp. (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, continues to demonstrate how the study of rare disease can improve understanding of the biology of common...
Jan 31, 2023 04:15 pm ET
GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering
GeneDx Holdings Corp. (Nasdaq: WGS) today announced the closing of its previously announced underwritten public offering of shares of its Class A common stock (the “Underwritten Offering”) and concurrent registered direct offering of shares of its...
Jan 30, 2023 08:30 am ET
GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery
Throughout 2022, GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, contributed a significant amount – 22% – of total candidate gene submissions to GeneMatcher, a platform that facilitates...
Jan 27, 2023 06:00 am ET
GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering
GeneDx Holdings Corp. (Nasdaq: WGS) today announced the pricing of offerings for an aggregate of 428,571,429 shares of its Class A common stock at a public offering price of $0.35 per share (the “Offerings”). The Offerings consist of an...
Jan 26, 2023 04:53 pm ET
GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it intends to commence an underwritten public offering of its Class A common stock. In addition, GeneDx...
Jan 09, 2023 08:30 am ET
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
Sema4 (Nasdaq: SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.